New cyclic butyrophenone derivatives in the indole series as potential atypical antipsychotics. A simple and practical synthesis of 6-aminomethyl-tetrahydroindol-4-ones and their affinities for D2 and 5-HT(2A) receptors

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 7, 1997, Pages 913-918

  Masaguer, Christian F ^a   Raviña, Enrique ^a   Loza, Isabel ^a   Fontenla, José Angel ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 ETHYL 6 [4 (4 FLUOROBENZOYL)PIPERIDINO]METHYL] 4,5,6,7 TETRAHYDRO 2 METHYLINDOL 4 ONE; BUTYROPHENONE DERIVATIVE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; MOLINDONE; NEUROLEPTIC AGENT; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; IN VITRO STUDY; METHODOLOGY; NONHUMAN; RAT; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

EID: 0030907274     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)00131-5     Document Type: Article

References (27)

1. This work was presented in the XIVth International Symposium on Medicinal Chemistry. Maastricht, The Netherlands, September 1996.
2. Kaiser, C.; Setler, P. E. Antipsychotic Agents in Burger's Medicinal Chemistry, 4th ed. Wolf, M. E., Ed., Wiley-Interscience: New York, 1981; part III, p 859.
3. (a) Lednicer, D.; Mitscher, L. A. The Organic Chemistry of Drug Synthesis; Wiley-Interscience, 1980; vol. 2, p 4559.
4. (b) Horu A. S. Dopamine Receptors in Comprehensive Medicinal Chemistry; Hansch, C.; Sammes, P. G.; Taylor, J. B., Eds.; Pergamon Press: Oxford, 1990; vol. 3, p 133.
5. For a review of pharmacological properties and therapeutic uses of clozapine see Fitton, A.; Heel, R. C. Drugs 1990, 40, 722.
6. (a) Meltzer, H. Y. Psychopharmacology 1989, 99, 18;
7. (b) Howard, R. H.; Lowe, J. A.; Seeger, T. F.; Seymour, P. A.; Zoru, S. H.; Maloney, P. R.; Ewing, F. E.; Newman, M. E.; Schmidt, A. W.; Furman, J. S.; Robinson, G. L.; Jackson, E.; Johnson, C.; Morrone, J. J. Med. Chem. 1996, 39, 143.
8. Ereshevsky, L.; Watanabe, N. D.; Trau-Johnson, T. K. Clin. Pharm. 1989, 8, 691.
9. (a) Meltzer, H. Y. ; Matsubara, S.; Lee, J. C. J. Pharmacol. Exp. Ther. 1989, 251, 238 ;
10. (b) Meltzer, H. C. ; Matsubara, S.; Lee, J. C. Psychopharmacol. Bull. 1989, 253, 390. See also IBC's International Conference on Serotonin Receptors in the SNC. Targets for new therapeutic agents. January, 25-26th. 1966. Philadelphia. USA.
11. (b) Meltzer, H. C. ; Matsubara, S.; Lee, J. C. Psychopharmacol. Bull. 1989, 253, 390. See also IBC's International Conference on Serotonin Receptors in the SNC. Targets for new therapeutic agents. January, 25-26th. 1966. Philadelphia. USA.
12. Raviña, E.; Masaguer, C. F.; Cid, J.; Casariego, I.; Fontenla, J. A.; Ferreiro, T. G.; Cadavid, M. I.; Loza, M. I. ; de Ceballos, M. Bioorg. Med. Chem. Lett. 1995, 5, 579.
13. Cortizo, L.; Santana, L.; Raviña, E.; Orallo, F.; Fontenla, J. A.; Castro, E.; Calleja, J. M.; de Ceballos, M. L. J. Med. Chem. 1991, 24, 2242.
14. Fontenla, J. A.; Osuna, J.; Rosa, E.; Castro, E.; Ferreiro, T. G.; Loza, M. I.; Calleja, J. M.; Sanz, F.; Rodriguez, J.; Raviña, E.; Fueyo, J.; Masaguer, C. F.; Vidal, A.; de Ceballos, M. L. J. Med. Chem 1994, 37, 2564.
15. Raviña, E.; Fueyo, J.; Masaguer, C. F.; Negreira, J.; Cid, J.; Loza, I.; Tristan, H.; Ferreiro, T. G.; Fontenla, J. A.; Rosa, E.; Calleja, J. M.; de Ceballos, M. L. Chem. Pharm. Bull. 1996, 44, 534.
16. Loza, I.; Castro, E.; Fontenla, J. A.; Calleja, J. M.; Raviña, E.; Cortizo, L.; de Ceballos, M. L. Bioorg. Med. Chem. Lett. 1991, 1, 1771.
17. (a) Boswell, R. F.; Welstead, W. J.; Duncan, R. C.; Funderburk, W. H. J. Med. Chem. 1978, 21, 136;
18. (b) Herndon, J. L.; Ismaiel, A.; Ingher, S. P.; Teitler, M.; Glennon, R. A. J. Med. Chem. 1992, 35, 4903.
19. 2A receptor interactions; a key structural feature that may play a prominent role in these interactions would be the benzylic carbonyl group (Ismaiel, A. M.; Arruda, K.; Teitler, M.; Glennon, R. A. J. Med. Chem. 1995, 38, 1196).
20. (a) Shustke, G. M.; Setescak, L. L.; Allen, R. C.; Davis, L.; Effland, R. E.; Ranbom, K.; Kitzen, J. M.; Wilker, J. C.; Novick, W. J. J. Med. Chem. 1982, 25, 36;
21. (b) Strupezewski, J. T.; Allen, R. C.; Gardenr, B. A.; Schmid, B. L.; Stache, U ; Glankowski, E. J.; Jones, M. C.; Ellis, D. B.; Huger, F. P.; Dunn, R. W. J. Med. Chem. 1985, 28, 761.
22. Masaguer, C. F. ; Raviña, E. Tetrahedron Lett. 1996, 37, 5171.
23. 1H-NMR and FTIR). Yields given correspond to isolated pure compounds.
24. Kuehne, M. E.; Lambert, B. F. J. Org. Chem. 1959, 21, 4278.
25. Chapman, O. L.; Fitton, P. J. Org. Chem. 1963, 25, 41.
26. 3) δ: 7.99 (dd, 2H, J=8.9 Hz, J=5.4 Hz), 7.88 (s, 1H), 7.12 (t, 2H, J=8.6 Hz), 2.97 (t, 2H, J=7.1 Hz), 2.90-2.82 (m, 1H), 2.68-2.59 (m, 2H), 2.57-2.23 (m, 15H), 2.21-2.11 (m, 4H), 1.93 (q, 2H, J=7.1 Hz), 1.11 (t, 3H, J=7.4 Hz).
27. Cheng, Y. C.; Prusoff. W. Biochem. Pharmacol. 1973, 22, 3099.